Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

Abstract

Our study demonstrates a long-term persistence of anti-RBD antibodies that may reduce risk of reinfection. By significantly increasing cross-neutralizing antibody titers, a single-dose vaccination strengthens protection against variants. FUN1DING: None.